Search Results
Your search for ,USE matches 11257 pages
Showing 2351 - 2400Assessing Food Insecurity Among Patients With Cancer
Food insecurity, particularly as it affects cancer survivors, is a serious problem, according to a survey of oncology registered dietitian nutritionists (RDNs) published in the Journal of the Academy of Nutrition and Dietetics.1 “Despite these concerns, most oncology RDNs interviewed are not using...
Music Interventions for Improving Psychological and Physical Symptoms in People With Cancer
Guest Editor’s Note: Cancer and its treatments are associated with both physical and psychological symptoms that can have substantial impact on patients’ quality of life. Music therapy is a complementary modality that is being increasingly used for cancer symptom management. In this article, Joke...
DESTINY-Lung01: Is Trastuzumab Deruxtecan the Answer for HER2-Mutant Lung Cancer?
The human epidermal growth factor (HER) family of receptors are a well-established therapeutic target. Indeed, seminal studies conducted nearly 2 decades ago identified a key association between activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR, also known as...
ASCO Honors 2022 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2022 ASCO Annual Meeting in Chicago. Hear from select award...
Updated Overall Survival Results From MONALEESA-3 Show Improved Overall Survival in Patients With HR-Positive/HER2-Negative Breast Cancer
In an updated analysis of the phase III MONALEESA-3 trial, which included postmenopausal patients with advanced/metastatic hormone receptor (HR)-positive, HER2-negative breast cancer, first-line treatment with ribociclib plus fulvestrant lengthened overall survival by approximately 16 months vs...
Neoadjuvant Nivolumab and Platinum-Doublet Chemotherapy for Early NSCLC
On March 4, 2022, nivolumab was approved for use with platinum-doublet chemotherapy for resectable non–small cell lung cancer (NSCLC) in the neoadjuvant setting.1 The approval is the first for neoadjuvant therapy for early-stage NSCLC. Supporting Efficacy Data Approval was based on findings from...
Natural Killer Cells Precomplexed With Innate Cell Engager Show Activity in CD30-Positive Lymphoma
Natural killer (NK) cells derived from donated umbilical cord blood, activated with a novel bispecific antibody targeting CD16A and CD30 known as AFM13, have yielded responses in patients with pretreated and refractory CD30-positive lymphoma. The overall response rate was 89%, with 53% complete...
Going the Last Mile: Accelerating Delivery of Multiple Myeloma Therapies to All Patients
When I was diagnosed with multiple myeloma in 1996, I was given 3 years to live. At the time, there was little understanding of this disease, which was termed incurable. There were no new treatments, few drugs in the pipeline, hardly any clinical trials, and no multiple myeloma community or...
2-Year Follow-up Shows Durable Responses With Sotorasib in KRAS G12C–Mutated Non–Small Cell Lung Cancer
Sotorasib, the first KRAS G12C inhibitor approved for the treatment of KRAS G12C–mutated non–small cell lung cancer (NSCLC), continues to demonstrate meaningful and durable efficacy at 2-year follow-up in the phase II CodeBreaK 100 trial. At a median follow-up of 24.9 months, the 2-year overall...
Hematologic Oncology 2021–2022 Almanac
Ongoing evaluation of novel, targeted, and immunotherapies has led to exciting advances across the array of hematologic malignancies over the past year. The availability of new treatment options, along with emerging data on novel combinations and sequencing approaches, is rapidly changing...
Bispecific Antibodies With Multiple Targets Moving Forward in Multiple Myeloma
Poor outcomes are observed in patients with myeloma who are refractory to multiple classes of therapies, with the average patient experiencing disease progression in up to 6 months and living no longer than 6 to 15 months. Patients often rapidly cycle through regimens that use less effective or...
Expert Point of View: Joseph Mikhael, MD
The ASCO Post asked Joseph Mikhael, MD, Chief Medical Officer of the International Myeloma Foundation and Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (an affiliate of City of Hope Cancer Center), to comment on the GMMG-HD7...
Isatuximab-Containing Induction Therapy for Multiple Myeloma Increases Measurable Residual Disease Negativity
For the first-line treatment of newly diagnosed multiple myeloma, the percentage of patients achieving measurable residual disease (MRD, previously called minimal residual disease) negativity was significantly greater when the anti-CD38 monoclonal antibody isatuximab was added to a standard...
MAIA Trial: Daratumumab Added to Lenalidomide Plus Dexamethasone Improves Overall Survival in Transplant-Ineligible Multiple Myeloma
As reported in The Lancet Oncology by Thierry Facon, MD, of the Centre Hospitalier Universitaire de Lille, and colleagues, a prespecified interim analysis of overall survival in the pivotal phase III MAIA trial has shown a significant benefit with the addition of daratumumab to...
POLARIX: Addition of Polatuzumab Vedotin-piiq to Standard of Care Significantly Reduces Progression of Diffuse Large B-Cell Lymphoma
As a first-line treatment of inter-mediate- or high-risk diffuse large B-cell lymphoma, the addition of the antibody-drug conjugate polatuzumab vedotin-piiq to standard-of-care therapy resulted in a 27% reduction in the relative risk of disease progression, relapse, or death, with a similar safety...
Expert Point of View: Laurie H. Sehn, MD, MPH and Alex Herrera, MD
Laurie H. Sehn, MD, MPH, Clinical Professor with the BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, Canada, and Alex Herrera, MD, Associate Professor in Hematology and Hematopoietic Cell Transplantation at the Beckman Research Institute of City of Hope,...
Expert Point of View: Susan M. O’Brien, MD
The GAIA trial raises some important points, according to Susan M. O’Brien, MD, Associate Director for Clinical Research at the UCI Chao Family Comprehensive Cancer Center in Irvine, California. Dr. O’Brien co-moderated the session where Dr. Eichhorst presented study results. “The CLL14 trial...
Expert Point of View: Jacqueline C. Barrientos, MD, MS
Invited study discussant Jacqueline C. Barrientos, MD, MS, of Northwell Health Cancer Institute, Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, commented: “The BTK [Bruton’s tyrosine kinase] inhibitors ibrutinib and acalabrutinib, along with the BCL2 inhibitor venetoclax, are ...
Deborah K. Armstrong, MD, on the Rationale for Intraperitoneal Treatment of Ovarian Cancer
Abstract discussant Deborah K. Armstrong, MD, of Johns Hopkins Kimmel Cancer Center Baltimore, elucidated the rationale for intraperitoneal (IP) treatment, which is the peritoneal pharmacokinetic advantage for many drugs used in ovarian cancer, including carboplatin, as used in the iPocc trial.1 In ...
Intraperitoneal Carboplatin Plus Paclitaxel vs Intravenous Chemotherapy in Ovarian Cancer
When compared with intravenous (IV) chemotherapy, the use of intraperitoneal (IP) carboplatin with dose-dense weekly paclitaxel improved progression-free survival in patients with ovarian, fallopian tube, or primary peritoneal carcinoma, according to data presented at the 2022 Society of...
Can AI Assist in Predicting Spinal Fractures in Patients With Cancer?
A new study published by Ahmadian et al in the International Journal for Numerical Methods in Biomedical Engineering suggests how scientists may use artificial intelligence (AI) to predict how cancer may affect the probability of fractures along the spinal column. The report described how the...
Study Examines Link Between Emphysema and Lung Cancer Risk
Computed tomography (CT)-detected emphysema may be linked to a higher risk of lung cancer, a risk that increases with emphysema severity, according to a new study published by Yang et al in the journal Radiology. Lung cancer is the primary cause of cancer-related death worldwide. However, lung...
Cemiplimab-rwlc Improves Overall Survival vs Chemotherapy in Recurrent Cervical Cancer After First-Line Platinum-Based Chemotherapy
As reported in The New England Journal of Medicine by Krishnansu S. Tewari, MD, of the Division of Gynecologic Oncology, University of California, Irvine, and colleagues, the phase III EMPOWER-Cervical1/GOG-3016/ENGOT-cx9 trial has shown improved overall survival with cemiplimab-rwlc vs...
Concordance With Pretreatment Staging Imaging Guidelines in Rectal Cancer: ASCO QOPI Findings
In an analysis from the ASCO Quality Oncology Practice Initiative (QOPI) reported in JCO Oncology Practice, Chen et al found that a high proportion of patients with rectal cancer do not receive guideline-recommended pretreatment staging transrectal ultrasound or pelvic magnetic resonance imaging...
Rates of Neurologic Adverse Events in Randomized Trials of Immune Checkpoint Inhibitors in Patients With Cancer
In a meta-analysis reported in JAMA Network Open, Farooq et al found that immune checkpoint inhibitor therapy for cancer was associated with a lower risk of neurologic adverse events compared with treatment with other agents overall in randomized trials comparing immune checkpoint inhibitors with...
Gut Microbiome May Alter Response to Cancer Therapy
Recent findings with the use of sequencing technology have suggested that the gut microbiome may play a role in the treatment of cancer. A review paper published in JAMA Oncology by Liu and Shah captured the current understanding of the connection between the gut microbiome and therapeutic response ...
SORAYA Trial: Mirvetuximab Soravtansine Improves Response Rate in Drug-Resistant Ovarian Cancer
The novel antibody-drug conjugate mirvetuximab soravtansine could become the new standard of care for patients with folate receptor alpha–positive, platinum-resistant ovarian cancer, according to data presented at the Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer.1...
Updated Guidance for COVID-19 Vaccination From NCCN Recommends Fifth mRNA Shot (Second Booster Dose) for Immunocompromised People
The National Comprehensive Cancer Network® (NCCN®) has released the latest recommendations from the NCCN Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis. The updated recommendations point to two booster vaccine doses for people who are immunocompromised (meaning three...
Some Recurrences of Ductal Carcinoma In Situ May Be Genetically Distinct From the Primary Tumor, Study Reports
Contrary to what has been assumed, all recurrences of ductal carcinoma in situ (DCIS) are not genetically the same, according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2022.1 Almost 20% of ipsilateral recurrences found in the study were genetically...
Two Studies Examine Use of Proton-Beam Therapy in the United States
Two new, large studies led by researchers at the American Cancer Society showed an increase in the use of proton-beam therapy for patients with cancer in the United States during the past decade. However, Black patients were less likely to receive proton-beam therapy than White patients, and the...
Study Examines Rates of Psychiatric Disorders and Self-Harm Among Patients Diagnosed Across 26 Cancer Types
The risk of self-harm after incident psychiatric disorder diagnosis in patients with 26 cancer types and the risk of unnatural deaths after self-harm were examined in 459,542 individuals in a study published by Chang et al in Nature Medicine. Patients with cancer may experience substantial...
AI May Assist Physicians in Better Assessing the Effectiveness of Bladder Cancer Treatment
In a small multi-institutional study, an artificial intelligence (AI)-based system improved providers’ assessments of whether patients with bladder cancer had complete response to chemotherapy before a radical cystectomy. These findings were published by Sun et al in Tomography. Yet the researchers ...
Expert Point of View: Mikkael Sekeres, MD
Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System and a hematologist at Sylvester Comprehensive Cancer Center, applauded the IDIOME1 and IDEAL2 investigators for conducting studies. These studies, he noted, were “very difficult because of the rarity...
Association of Lifestyle and Cardiovascular Risk Factors With Hospitalization for Heart Failure Subtypes in Breast Cancer Survivors
In an analysis from the Women’s Health Initiative reported in JACC: CardioOncology, Kerryn W. Reding, PhD, MPH, RN, of the University of Washington at Seattle, and colleagues, identified the incidence of hospitalization for heart failure among postmenopausal breast cancer survivors. They reported...
Immune Checkpoint Inhibitors in Neoadjuvant or Adjuvant Therapy for Triple-Negative Breast Cancer: The Paradigm Shifts
The “holy grail” of triple-negative breast cancer therapy has been effective incorporation of drugs to improve outcomes in the early nonmetastatic setting. Although outcomes have improved with better chemotherapy drugs and schedules, triple-negative breast cancer still carries the worst prognosis...
MEK Inhibition Is Now a Standard of Care in Recurrent Low-Grade Serous Ovarian Cancer: What Next?
As summarized in this issue of The ASCO Post, the highly anticipated results of the GOG 281/LOGS study, which randomly assigned patients with recurrent low-grade serous ovarian cancer to the MEK inhibitor trametinib vs standard-of-care chemotherapy or endocrine therapy, have now been reported by...
Fixed-Dose Nivolumab and Relatlimab-rmbw for Unresectable or Metastatic Melanoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 18, 2022, fixed-dose nivolumab and...
New Report Offers Guidance for Standardizing Data on Sex, Gender, Sexual Orientation
On March 9, 2022, the National Academies of Sciences, Engineering, and Medicine (NASEM) issued a new report, Measuring Sex, Gender Identity, and Sexual Orientation, recommending the National Institutes of Health (NIH) implement new guidelines to standardize the collection of data on sex, gender,...
War in Ukraine: Statistics Do Not Keep Pace With Reality
Editor’s Note: The following is adapted from Dr. Hrynkiv’s presentation at the March 18 ASCO/ECO Briefing: Cancer Care During the War in Ukraine. Find resources for impacted patients and providers at asco.org/ukraine and onco-help.org. Official statistics regarding damage and losses in Ukraine are...
Clinical Trials Updates in the Treatment of Older Adults With Gastrointestinal Malignancies
The theme of the 2022 ASCO Gastrointestinal Cancers Symposium was “Accelerating Access to Precision Care Through Innovation.” Several studies presented at this meeting focused on older patients, who represent the majority of patients with gastrointestinal malignancies. Data reviewed at the meeting...
Expert Point of View: Angela DeMichele, MD, MSCE
Abstract discussant, Angela DeMichele, MD, MSCE, the Alan and Jill Miller Professor in Breast Cancer Excellence at the Perelman School of Medicine of the University of Pennsylvania, Philadelphia, complimented the study design and conduct of the ABC trial while exploring several possible...
Phase III Trial Evaluates the Role of Aspirin in Preventing Breast Cancer Recurrence
Taking aspirin daily does not prevent breast cancer recurrence, according to research presented during the February ASCO Plenary Series Program.1 Results of the double-blind phase III study of more than 3,000 patients with high-risk, HER2-negative breast cancer showed no improvement in invasive...
Expert Point of View: Martin Reck, MD, PhD
The discussant of the PEARLS/KEYNOTE-091 trial, Martin Reck, MD, PhD, underscored the need to do more in the perioperative management of patients with early-stage non–small cell lung cancer (NSCLC) to improve rates of overall survival and relapse after surgery. Dr. Reck is Head of the Department of ...
Why Are Many Women Overdue for Cervical Cancer Screening?
Cervical cancer screening has reduced new cases and deaths from the disease over the past 50 years. However, the percentage of women in the United States who are overdue for cervical cancer screening has been growing, and the reasons have not been clear. To better understand the decline in cervical ...
Expert Point of View: Charu Aggarwal, MD, MPH
Charu Aggarwal, MD, MPH, discussant of the CHOICE-01 trial, underscored the “tremendous progress” that’s been made over the past 2 decades in the management of metastatic non–small cell lung cancer, with overall survival increasing from less than 1 year with the use of combination chemotherapy to...
CHOICE-01: Toripalimab Plus Chemotherapy Improves Survival in Advanced NSCLC Without Actionable Mutations
Adding the PD-1 inhibitor toripalimab to chemotherapy significantly improved survival compared with chemotherapy alone in patients with advanced non–small cell lung cancer (NSCLC) without EGFR/ALK mutations, according to research presented during the 2022 ASCO Monthly Plenary Series.1 At the...
Is Neoadjuvant Pembrolizumab Underused in the Treatment of Early-Stage Triple-Negative Breast Cancer?
Neoadjuvant pembrolizumab has been approved in combination with chemotherapy for high-risk, early-stage, triple-negative breast cancer, but not all patients with node-positive disease have been able to receive the regimen, according to data presented during the Society of Surgical Oncology 2022...
Phase III Trials and Tribulations
Imagine this. You are a large pharmaceutical company that launches an international randomized phase III trial to assess whether one of your drugs improves the outcome of patients with a common type of cancer. The trial was solidly backed by preclinical evidence that the drug target was essential ...
Study Shows Pemigatinib Activity in Treatment of Myeloid or Lymphoid Neoplasms With FGFR1 Rearrangement
In patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements, pemigatinib produced high and durable response rates, despite patients’ extensive use of prior treatments or hematopoietic stem cell transplantation (HSCT), according to the early results of the multicenter phase II FIGHT-203 ...
Tislelizumab Plus Chemotherapy Improves Progression-Free Survival in Nasopharyngeal Cancer
The addition of the checkpoint inhibitor tislelizumab to first-line chemotherapy significantly reduced the risk of disease progression or death by 50% and, despite a 49% crossover rate, numerically boosted overall survival in patients with recurrent or metastatic nasopharyngeal cancer, Zhang et al...
